AUSSENDER
AOP Orphan Pharmaceuticals AG
AOP Orphan Pharmaceuticals AG
Ansprechpartner:
Dr. Christoph Klade
Tel.:
E-Mail: christoph.klade@aoporphan.com
Schlagwörter:
  • AOP Orphan Pharmaceuticals AG

  • EMA

  • Ropeginterferon alfa-2b
WETTER
Graz: wolkig
15°
Innsbruck: heiter
19°
Linz: heiter
14°
Wien: heiter
13°
© wetter.net

Stadtname / PLZ
AKTIENKURSE
 
Pressefach
Sa, 25.03.2017
AOP Orphan Pharmaceuticals Aktiengesellschaft  (7 Meldungen)
AOP Orphan Pharmaceuticals AG
AOP Orphan Pharmaceuticals AG announces start of EMA marketing authorization application procedure for Ropeginterferon alfa-2b in Polycythemia Vera * EMA started the centralized marketing authorization procedure for Ropeginterferon alfa-2b for treat(...)
AOP Orphan starts EMA marketing authorization application procedure for Ropeginterferon alfa-2b
2017-03-14, pts20170314032 Medizin/Wellness, Produkte/Innovationen
AOP Orphan and PharmaEssentia announce pivotal phase III results for ropeginterferon alfa-2b in PV
2016-12-05, pts20161205017 Forschung/Technologie, Medizin/Wellness
AOP Orphan and PharmaEssentia announce pivotal phase III results for ropeginterferon alfa-2b in PV
2016-12-05, pts20161205006 Forschung/Technologie, Medizin/Wellness
AOP Orphan announces European approvable opinion of its ultra-short acting beta blocker Rapibloc®
2016-07-11, pts20160711014 Medizin/Wellness, Produkte/Innovationen
AOP Orphan announces European approvable opinion of its ultra-short acting beta blocker Rapibloc®
2016-07-11, pts20160711013 Medizin/Wellness, Produkte/Innovationen
Roland Bindeus wechselt von Baxalta zu AOP Orphan
2016-04-05, pts20160405030 Medizin/Wellness, Bildung/Karriere